NCT03875235 2026-03-19
TOPAZ-1
AstraZeneca
Phase 3 Active not recruiting
Clinical Trials
15 trialsNCT07221253 2026-03-17
AB02
AstraZeneca
Phase 3 Recruiting
NCT03847428 2026-03-06
EMERALD-2
AstraZeneca
Phase 3 Active not recruiting
NCT06282575 2026-02-24
Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer
Jazz Pharmaceuticals
Phase 3 Recruiting
NCT05771480 2026-02-23
TOURMALINE
AstraZeneca
Phase 3 Active not recruiting
NCT05883644 2026-02-18
SIERRA
AstraZeneca
Phase 3 Active not recruiting
NCT06467357 2026-02-17
DESTINY-BTC01
AstraZeneca
Phase 3 Recruiting
NCT04550260 2026-01-29
KUNLUN
AstraZeneca
Phase 3 Active not recruiting
NCT07229625 2026-01-28
A Phase III Study of SHR-8068 in Combination With Adebrelimab and Platinum-Containing Chemotherapy Versus Durvalumab in Combination With Platinum-Containing Chemotherapy as First-line Treatment for Advanced Biliary Tract Cancer (BTC)
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 3 Recruiting
NCT06591520 2026-01-21
AK112 Combined With Chemotherapy Versus Durvalumab Combined With Chemotherapy in Advanced Biliary Tract Cancer
Akeso
Phase 3 Active not recruiting
NCT03778957 2026-01-16
EMERALD-1
AstraZeneca
Phase 3 Active not recruiting
NCT03298451 2026-01-14
HIMALAYA
AstraZeneca
Phase 3 Active not recruiting
NCT05924880 2025-04-22
TopDouble
AstraZeneca
Phase 3 Completed
NCT05557838 2025-02-07
TREMENDOUS
AstraZeneca
Phase 3 Recruiting
NCT05301842 2025-01-15
EMERALD-3
AstraZeneca
Phase 3 Active not recruiting